Etteplan publishes its Q1 results on 8th of May. We expect year-on-year revenue growth boosted by ac...
12% organic growth on tough P&S comps... ...while we expect an acceleration from Q2 Trading at ~6x '...
We cut '24e and '25e EBITDA by 17% and 8% Refocusing of Aurdel to improve margin stability '25e EV/E...
Q1e: still some de-stocking weighing on Medical Minor revisions, '25e-'26e EBITA up by 1% on FX Stro...
M&A to drive growth while organically flat, EBITA margin to hold up H1 weakness in EMS industry, but...
Føroya Banki (formerly BankNordik) reported Q1 2024 pre-tax profit DKK 15m (19%) below our estimate,...
Ahead of Suominen’s Q1 report, due on 7 May, we maintain our estimates intact.
Orviglance meets the primary endpoint in the SPARKLE study with a p-value of
Relais’ Commercial vehicle repair and maintenance company Raskone announced today acquisition of Ase...
On the right track after a challenging 2023 Positive revisions, 10% EBIT margins looks achievable We...
Spago Nanomedical’s Phase I/IIa study, Tumorad-01, is progressing with a steady OPEX base in line wi...
Redeye briefly comments on Enviro’s press release, which stated that Enviro has received a second pa...
Sales -2% vs. ABGSCe, -7% y-o-y Ework expects sales to decline H1'24 but to recover in H2'24 We expe...
Q1 rapporten kom in något sämre än Analysguidens prognos och marknaden reagerade surt på rapporten o...
En historisk milstolpe har realiserats då AcuCort AB (”AcuCort” eller ”Bolaget”) har erhållit en för...
Redeye presents its preview for Devyser’s Q1 2024 report, which is due on May 8.
Q1 2024 profit before loan losses came in at DKK 70m, DKK 4m (6%) ahead of our estimate.
See what other investors are asking and the answers from Redeye's dedicated analyst in the latest An...
Redeye comments on Raketech’s preliminary Q1-results which are lower than expected as the company ha...
Slutlig studiedesign närmar sig Medivir har fullt fokus på att ta fostrox framåt mot en registrering...
